FarmaKology Newsletter - Issue #1
FarmaKology Newsletter - Issue #1
The FDA has dashed Sanofi's hopes of launching its type I diabetes drug, Zynquista, this year.
News
FDA rejects oral Type I diabetes drug
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Sanofi’s type I diabetes drug, Zynquista (sotagliflozin).
NICE recommend Takeda's lymphoma treatment Adcetris
Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma (CTCL).
Alzheimer’s trial discontinued due to inefficiency
Biogen and Eisai have stopped two global Phase III trials of the Alzheimer's drug aducanumab, after interim analyses indicated that the agent was ineffective and would not meet the primary endpoint.
Bayer and Johnson & Johnson Settle Lawsuits Over Xarelto, a Blood Thinner, for $775 Million
The settlement resolves about 25,000 lawsuits, which claimed the companies failed to warn about deadly bleeding episodes caused by the drug.
Research
Multi-drug approach found to attack resistance in bowel cancer
Digital Intervention Ups Socialization in Children With Autism
Podcasts
Job Opportunities
Advanced Clinical Pharmacist EFL JFK
Clinical Pharmacist - Butterworth Hospital
Pharmacist
Consultant Pharmacist
